TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3518527
Drug: Purified and
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified and standardized Cladosporium herbarum allergen preparation (active treatment)
Study: 31331339
Drug: Routine follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine follow-up (RFU) with one extra medical visit and additional visits to the Cardiology and Respiratory Medicine Clinics 1 and 3 months postoperatively
Study: 28836375
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing (MI) session before periodontal treatment
Study: 28836375
Drug: Conventional educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional educational intervention and non-surgical periodontal therapy
Study: 24681572
Drug: Nitrate-rich concentrated
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich concentrated beetroot juice (NIT; nitrate dosage, approximately 9.7 mmol·d)
Study: 17549677
Drug: Levofloxacin formulation
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin formulation product after oral administration
Study: 16208152
Drug: HCTZ 25
Normalized name: HCTZ 25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 25 mg added to olmesartan 20 mg
Study: 16208152
Drug: Olmesartan/HCTZ 20/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/HCTZ 20/12.5 mg
Study: 16208152
Drug: Olmesartan/HCTZ 20/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/HCTZ 20/25 mg
Study: 9893775
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release oral salbutamol (CR) 8 mg b.d. for > or = 3 days
Study: 9893775
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled salmeterol xinafoate (SX) 100 micrograms b.d. for > or = 3 days
Study: 15465995
Drug: High-dose omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omega-3 fatty acids
Study: 10770448
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (100-300 mg/day)
Study: 10817105
Drug: Paroxetine (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10-40 mg/day)
Study: 8788597
Drug: FK453 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK453 (50 mg)
Study: 8788597
Drug: FK453 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK453 (200 mg)
Study: 6436935
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg sustained release theophylline
Study: 6436935
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg sustained release theophylline
Study: 6436935
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg and 450 mg sustained release theophylline
Study: 30696471
Drug: Automated VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated VR cognitive treatment
Study: 20183394
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy processes measured by the Working Alliance Inventory‐Short Form
Study: 17973865
Drug: N(G)-monomethyl-L-arginine (L-NMMA)
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-monomethyl-L-arginine (L-NMMA) at 1 mmol/L
Study: 17973865
Drug: Asymmetric dimethylarginine
Normalized name: dimethylamine
DrugBank: N,N-dimethylarginine (DB01686)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asymmetric dimethylarginine (ADMA) at 1 mmol/L
Study: 17973865
Drug: L-leucine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-leucine at 1 mmol/L
Study: 11502777
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone therapy (32 patients treated)
Study: 11502777
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone therapy (in responders)
Study: 11502777
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (in responders)
Study: 7508066
Drug: diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: diet and fluid plus indapamide 2.5 mg/day (group B)
Study: 7508066
Drug: diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: diet and fluid plus indapamide 2.5 mg/day plus allopurinol 300 mg/day (group C)
Study: 3106449
Drug: Sodium Cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Cromoglycate (SCG) (10 mg)
Study: 2685081
Drug: Amiodarone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (200 mg every 8 h for 2 weeks, then 200 mg/day)
Study: 31976548
Drug: Tetramethylpyrazine (TMP)
Normalized name: Tetramethylpyrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetramethylpyrazine (TMP) 100 mg·kg‐1 ·day‐1 in animal models (Sprague-Dawley rats)
Study: 31976548
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of TMP (100 mg, t.i.d. for 16 weeks) in a small cohort of patients with PAH or CTEPH
Study: 22911223
Drug: bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine plus epinephrine 100 μg
Study: 22911223
Drug: bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine plus epinephrine 200 μg
Study: 15198841
Drug: Weekly fructosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly fructosamine testing in addition to daily glucose monitoring (Group 1)
Study: 15198841
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care of daily glucose monitoring (Group 2)
Study: 3567122
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of salbutamol orally five times daily
Study: 24818633
Drug: COBRA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA therapy (methotrexate 7.5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day)
Study: 24818633
Drug: COBRA-light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA-light therapy (methotrexate increased to 25 mg/week with initial prednisolone 30 mg/day)
Study: 23278964
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive fractional bipolar radiofrequency (FRF) treatment
Study: 18199590
Drug: Fructose drink
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose drink (60 g in 500 ml)
Study: 18199590
Drug: Glucose drink
Normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose drink (60 g in 500 ml)
Study: 16442153
Drug: BAY 12‐9566
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 12‐9566 (tanomastat) 800 mg p.o. b.i.d.
Study: 14615615
Drug: Anticoagulation (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation (5-10 day course of full-dose low-molecular-weight heparin followed by 3 months of lower-dose low-molecular-weight heparin)
Study: 11739865
Drug: Liver paste
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver paste (3.0, 7.5, or 15 mg vitamin A)
Study: 11739865
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplement (3.0, 7.5, or 15 mg vitamin A)
Study: 9239992
Drug: Leucine supplementation
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine supplementation (50.0 +/- 3.3 mg/kg body weight per day)
Study: 31529084
Drug: Oral sugar
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sugar enriched expressed breastmilk (EBM)
Study: 31529084
Drug: IV dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dextrose therapy (IVDx)
Study: 31188728
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (finasteride plus doxazosin)
Study: 23248072
Drug: Opicapone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 10 mg
Study: 23248072
Drug: Opicapone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 100 mg
Study: 23248072
Drug: Opicapone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 200 mg
Study: 23248072
Drug: Opicapone 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 400 mg
Study: 23248072
Drug: Opicapone 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 800 mg
Study: 23248072
Drug: Opicapone 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 1200 mg
Study: 23248072
Drug: Opicapone 50
Normalized name: opicapone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 50 mg with high-fat meal
Study: 23248072
Drug: Opicapone 50
Normalized name: opicapone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 50 mg fasting
Study: 18490378
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with sulfamethoxazole/trimethoprim for 2 years
Study: 18490378
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis with sulfamethoxazole/trimethoprim
Study: 12670781
Drug: cilomilast (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilomilast (15 mg)
Study: 1642114
Drug: Oxcarbazepine (OXC)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXC) 600 mg
Study: 6299159
Drug: Steroid/antibiotic combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid/antibiotic combination product (dexamethasone, neomycin, and polymyxin B) for three days prior to surgery and three weeks following surgery
Study: 6299159
Drug: Steroid/antibiotic combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid/antibiotic combination product
Study: 11573667
Drug: Ropivacaine 5
Normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 5 mg ml(-1) in glucose 50 mg ml(-1)
Study: 11573667
Drug: Ropivacaine 5
Normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 5 mg ml(-1) in glucose 10 mg ml(-1)
Study: 8955861
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation of selegiline HCl (4 x 5 mg tablets)
Study: 7013971
Drug: Radiotherapy-chemotherapy (RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy-chemotherapy (RT & CT)
Study: 28222742
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g HAM-RS2 muffins (n = 11)
Study: 28222742
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g HAM-RS2 muffins (control; n = 7)
Study: 16032784
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta‐carotene, 100 microg selenium, and 20 mg zinc)
Study: 12170041
Drug: Epidural top-up
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural top-up with 10 ml ropivacaine, 0.75% (group 1, n = 10)
Study: 25525981
Drug: LG3, LTBP2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LG3, LTBP2, Cathepsin L
Study: 20420579
Drug: Low-fat/high-complex carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat/high-complex carbohydrate diet supplemented with 1.24 g/day of long-chain n-3 polyunsaturated fatty acid (LFHCC n-3)
Study: 20420579
Drug: Low-fat/high-complex carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat/high-complex carbohydrate diet with 1 g/day of sunflower oil high in oleic acid (LFHCC)
Study: 18686769
Drug: Scaling/root planing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling/root planing plus test gel application (triclosan 1% + polydimethylsiloxane 13%)
Study: 18686769
Drug: Scaling/root planing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling/root planing plus control gel application (polydimethylsiloxane 13%)
Study: 15625365
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) ifosfamide (1.5 g/m2/d, days 1 through 4) plus doxorubicin (60 mg/m2)
Study: 15625365
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) ifosfamide (3.0 g/m2, days 1 through 4) plus doxorubicin (60 mg/m2)
Study: 10325738
Drug: Picolax (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picolax (sodium picosulphate 10 mg/sachet with magnesium citrate) and clear fluids
Study: 10325738
Drug: Bisacodyl tablets
Normalized name: Bisacodyl;Polyethylene Glycol 3350/Potassium Chloride/Sodium Bicarbonate/Sodium Chloride 5 MG; 210 GM-0.74 GM-2.86 GM-5.6 GM Oral Kit [HALFLYTELY & BISACODYL TABLETS BOWEL PREP]
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bisacodyl tablets with an unrestricted diet and a phosphate enema
Study: 8946103
Drug: Control toothpaste
Normalized name: Sodium Fluoride Dental Paste [TARTAR CONTROL TOOTHPASTE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control toothpaste containing no caries‐preventive agent
Study: 6703927
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (100 mg ASA + 75 mg DPM, t.d.s.)
Study: 6703927
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (300 mg ASA + 75 mg DPM, t.d.s.)
Study: 29719379
Drug: Orodispersible film
Normalized name: Ondansetron (as ondansetron hydrochloride) 8 mg orodispersible film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orodispersible film (ODF) of tadalafil (20 mg)
Study: 29719379
Drug: Film-coated tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablet (FCT) of tadalafil (20 mg)
Study: 22353022
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg weekly for 96 weeks
Study: 16282540
Drug: Basic rehabilitation
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic rehabilitation program with additional arm, leg, or air splint therapy
Study: 9481631
Drug: Zinc-fortified bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc-fortified bread providing 2 mg/kg/day elemental zinc acetate for 90 days
Study: 7874898
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg four times daily added to standard enteral nutrition feeding protocol
Study: 2404046
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg once a day)
Study: 2404046
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg three times a day)
Study: 2404046
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole (325 mg and 75 mg together three times a day)
Study: 2404046
Drug: Sulfinpyrazone (267
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfinpyrazone (267 mg three times a day)
Study: 369471
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of DTgammaE zinc phosphate daily intramuscularly for about seven days (study 1)
Study: 369471
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of nonlasting DTgammaE in saline daily intramuscularly for eight days (study 2)
Study: 369471
Drug: Neuroleptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic therapy maintained in six patients and drug-free in two patients (study 2)
Study: 15207200
Drug: Pharmaceutical intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical intervention in a monitoring programme for type-2 diabetics
Study: 9102059
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU intranasal calcitonin daily
Study: 9102059
Drug: 20 intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 intramuscular injections of 50 mg nandrolone decanoate plus placebo nasal spray
Study: 9102059
Drug: 20 injections
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 injections of 50 mg nandrolone decanoate plus 400 IU intranasal calcitonin daily
Study: 9102059
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate and intranasal calcitonin
Study: 22289649
Drug: Menaquinone-7 (MK-7)
Normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone-7 (MK-7) supplementation at doses around RDA (10, 20, 45, 90, 180, or 360 μg)
Study: 8644836
Drug: Pet therapy
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pet therapy intervention for 1 hr a day for 5 consecutive days
Study: 1996747
Drug: Propofol/Ketamine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/Ketamine combination
Study: 1996747
Drug: Propofol/Fentanyl combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/Fentanyl combination
Study: 24279638
Drug: Interdisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary treatment (12 sessions for 6 weeks)
Study: 24279638
Drug: Standard-of-care pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care pharmacologic treatment
Study: 18795255
Drug: AVAPS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVAPS therapy
Study: 18795255
Drug: NIV-PS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIV-PS therapy
Study: 15088288
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg daily by injection
Study: 9554521
Drug: Epirubicin, etoposide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin, etoposide, cisplatin, and lonidamine (EEP‐L)
Study: 9554521
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (5‐FU/6S‐LV and EEP‐L)
Study: 9554521
Drug: EEP‐L
Normalized name: Ethinyl Estradiol and Levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEP‐L
Study: 3046542
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine hydrochloride (Catapres‐TTS No. 2) treatment for one week
Study: 25403343
Drug: Oral topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral topiramate (TPM)
Study: 25403343
Drug: Intravenous topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous topiramate (TPM)
Study: 25403343
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 100 mg dose
Study: 15249451
Drug: Low‐radiation‐dose spiral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐radiation‐dose spiral CT (LDCT) scan
Study: 12034159
Drug: CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP levels >0.9 mg/dl
Study: 2524166
Drug: 10 ng.kg‐1.min‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ng.kg‐1.min‐1 ANF infusion
Study: 2524166
Drug: 25 ng.kg‐1.min‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ng.kg‐1.min‐1 ANF infusion
Study: 1119691
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without endocrine ablation
Study: 19333080
Drug: Purified chick
Normalized name: rabies vaccine, purified chick embryo cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified chick embryo cell rabies vaccine administered intramuscularly or intradermally
Study: 16394700
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia followed by patient-controlled analgesia with intravenous morphine
Study: 15235161
Drug: Indomethacin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.1 mg/kg/dose intravenously, 3 doses)
Study: 11726250
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate loading (20 g per day for 7 days)
Study: 2855221
Drug: Propranolol-adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol-adrenaline infusion
Study: 2855221
Drug: Supramaximal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supramaximal dose of GRF 1-44 (200 micrograms, i.v.)
Study: 24177278
Drug: Innovative dental
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovative dental implant design with tapered and cylindrical shape, placed under different protocols.
Study: 21164352
Drug: Olanzapine (16.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (16.2 mg for AA, 16.6 mg for CA)
Study: 17361520
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic treatment including liver protecting medicines, diuretics, and supportive drugs)
Study: 30442030
Drug: Prolonged slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged slow expiration respiratory physiotherapy treatment
Study: 30066937
Drug: Aloe polysaccharide
Normalized name: Aloe Polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe polysaccharide (APS) at doses of 20, 40, and 80 µg/ml
Study: 27217345
Drug: Low-dose ASCs
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ASCs (2 × 10(6) cells)